复星医药(02196.HK)与国药物流合作 配送BioNTech mRNA新冠疫苗
复星医药(02196.HK)与国药物流在上海举行关於BioNTech mRNA新冠疫苗配送合作签约仪式。由复星医药副总裁兼首席发展官李胜利与国药物流总经理顾一民分别代表双方公司签约。
双方将在全国范围内开展疫苗产品储存、配送以及供应链服务合作,此次签约仪式是在国药控股和复星医药签署物流战略合作的基础上,进一步细化在冷链物流各个环节合作,双方将发挥各自优势,在疫苗的商业化、物流与供应链建设等方面加强联动、协同发展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.